Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.
TIEFENBACHER GROUP and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health: combining traditional drug-based medicines with digital therapeutics and intelligent dosing
You are currently viewing a placeholder content from Default. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
